JP2023518707A - タンパク質症に関連する徘徊を治療する方法 - Google Patents

タンパク質症に関連する徘徊を治療する方法 Download PDF

Info

Publication number
JP2023518707A
JP2023518707A JP2022554548A JP2022554548A JP2023518707A JP 2023518707 A JP2023518707 A JP 2023518707A JP 2022554548 A JP2022554548 A JP 2022554548A JP 2022554548 A JP2022554548 A JP 2022554548A JP 2023518707 A JP2023518707 A JP 2023518707A
Authority
JP
Japan
Prior art keywords
wandering
patient
dementia
disease
fasudil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518707A5 (https=
Inventor
マカリスター，トーマス
ジェイコブソン，スヴェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of JP2023518707A publication Critical patent/JP2023518707A/ja
Publication of JP2023518707A5 publication Critical patent/JP2023518707A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022554548A 2020-03-25 2021-01-08 タンパク質症に関連する徘徊を治療する方法 Pending JP2023518707A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062994527P 2020-03-25 2020-03-25
US62/994,527 2020-03-25
US202063005913P 2020-04-06 2020-04-06
US63/005,913 2020-04-06
PCT/US2021/012587 WO2021194608A1 (en) 2020-03-25 2021-01-08 Methods of treating proteinopathy- associated wandering

Publications (2)

Publication Number Publication Date
JP2023518707A true JP2023518707A (ja) 2023-05-08
JP2023518707A5 JP2023518707A5 (https=) 2024-01-16

Family

ID=77855102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554548A Pending JP2023518707A (ja) 2020-03-25 2021-01-08 タンパク質症に関連する徘徊を治療する方法

Country Status (7)

Country Link
US (2) US11642352B2 (https=)
EP (1) EP4125879A4 (https=)
JP (1) JP2023518707A (https=)
CN (1) CN115916187A (https=)
CA (1) CA3170073A1 (https=)
MX (1) MX2022011518A (https=)
WO (1) WO2021194608A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
WO2021216139A1 (en) 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
MX2023000600A (es) * 2020-07-14 2023-02-13 Woolsey Pharmaceuticals Inc Metodos de tratamiento de proteinopatias.
CN118251226A (zh) * 2021-11-12 2024-06-25 悟而喜制药公司 治疗肌萎缩性侧索硬化症的方法以及其给药方案
US20240423998A1 (en) 2021-11-29 2024-12-26 Woolsey Pharmaceuticals, Inc. Methods of treating agitation and other dementia-associated behavioral symptoms
EP4479035A4 (en) * 2022-02-17 2026-02-25 Woolsey Pharmaceuticals Inc FASUDIL TASTE MASKING ORAL FORMULATIONS
CN118922193A (zh) * 2022-02-17 2024-11-08 悟而喜制药公司 具有离子交换树脂的法舒地尔口服制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3464012B2 (ja) 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
CN100444843C (zh) * 1998-08-10 2008-12-24 旭化成制药株式会社 法舒地尔盐酸盐缓释口服制剂
WO2005117896A1 (de) 2004-06-03 2005-12-15 Schering Aktiengesellschaft Formulierungen, die fasudil, eine matrix und einem mantel enthalten
WO2008036459A2 (en) * 2006-07-20 2008-03-27 Borchardt Allen J Inhibitors of rho kinase
WO2008019395A2 (en) 2006-08-10 2008-02-14 Translational Genomics Research Institute Compounds for improving learning and memory
US20080044390A1 (en) 2006-08-11 2008-02-21 Xiaowei Jin Methods and compositions for the treatment of neurodegenerative disorders
EP2285217A4 (en) 2008-05-12 2011-06-08 Amnestix Inc CONNECTIONS TO IMPROVE LEARNING AND MEMORY
CN101612157A (zh) 2008-06-26 2009-12-30 天津红日药业股份有限公司 法舒地尔诱导成年脑内源性神经干细胞再生的用途
US9980972B2 (en) 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
WO2017195224A1 (en) 2016-05-09 2017-11-16 Istituto Superiore Di Sanita' Rho gtpase activating bacterial toxins for use in the treatment of disorders of the central nervous system by mucosal administration
MX2022008513A (es) * 2020-01-09 2022-08-08 Woolsey Pharmaceuticals Inc Metodos para tratar la deambulacion asociada con la demencia cortical.
WO2021216139A1 (en) * 2020-04-23 2021-10-28 Woolsey Pharmaceuticals, Inc Methods of using rho kinase inhibitors to treat alzheimer's disease
MX2023000600A (es) * 2020-07-14 2023-02-13 Woolsey Pharmaceuticals Inc Metodos de tratamiento de proteinopatias.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010196A1 (en) * 2010-04-02 2012-01-12 Qin Quingyu Methods of treating neurodegenerative disorders and diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Fasudil hydrochloride ameliorates memory deficits in rat model of streptozotocin-induced Alzheimer's", BEHAVIOURAL BRAIN RESEARCH, vol. 351, JPN6025000162, 2018, pages 4 - 16, ISSN: 0005636683 *
"随一血管性痴呆患者の俳徊症状に対する塩酸fasudilの効果", 神経治療, vol. 13, no. 1, JPN6025000160, 1996, pages 43 - 50, ISSN: 0005636682 *
ALZHEIMER'S AND DEMENTIA, vol. Vol.11, O2-12-04, JPN6025028070, 20 July 2015 (2015-07-20), pages 203, ISSN: 0005636680 *
老年期認知症研究会誌, vol. 19, no. 5, JPN6025028071, 2012, ISSN: 0005636681 *

Also Published As

Publication number Publication date
EP4125879A4 (en) 2024-04-03
US11642352B2 (en) 2023-05-09
CA3170073A1 (en) 2021-09-30
MX2022011518A (es) 2022-10-07
WO2021194608A1 (en) 2021-09-30
EP4125879A1 (en) 2023-02-08
US20210299140A1 (en) 2021-09-30
US20230226073A1 (en) 2023-07-20
CN115916187A (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
US11642352B2 (en) Methods of treating wandering in Lewy dody dementia
JP7766935B2 (ja) 皮質性認知症に関連する徘徊を治療する方法
US11771704B1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
JP2023530120A (ja) 血管性認知症を治療するためのＲｈｏキナーゼ阻害剤の使用方法
US11311553B1 (en) Methods of treating 4-repeat tauopathies
US20230263806A1 (en) Methods of treating proteinopathies
EP4125910B1 (en) Rho kinase inhibitors for treating frontotemporal dementia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120